For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity. Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the next generation of researchers is poised to continue making progress for everyone affected by this

Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000 attendees from over 100 countries, this meeting gathered an international audience of clinicians, researchers, patient advocates, and representatives from the healthcare industry to discuss cutting-edge cancer research and share practice-changing clinical trial data. We saw data from studies that aim to build upon existing treatments, to optimize combination approaches, and to address some of the unmet needs of people

LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum—from early detection to treating advanced disease. “Today’s research is tomorrow’s cure. If we want to see continued breakthroughs and advancements in lung cancer, we must secure a strong pipeline of researchers dedicated to improving outcomes for people with lung cancer,” said Upal Basu Roy, PhD, MPH, Executive Director of Research at LUNGevity Foundation. “To continue the momentum in lung cancer progress, we must

Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community. Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made through sustained lung cancer research. 1. The Precancer Genome Atlas: Stopping Lung Cancer Before It

As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure. Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this disease to develop targeted approaches for early detection and treatment. As part of LUNGevity’s

The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In February, we welcomed Randi Williams, PhD, MPH, of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center. Her research focuses on methods to promote the adoption of evidence-based lung cancer control practices

Read time: 2 minutes. Here we present the final video in our three-part series about how patients and researchers can work together to develop clinical trials. In the video below, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to illustrate the power of having patients contribute to the research process. We use a real-world example to learn about patient-researcher collaborations through the POSITIVE study, a breast cancer-focused clinical trial. You can watch the entire video, or use the timestamps below. Make sure to watch parts 1 and 2 of this series here: How Can

Read time: 2 minutes. We are pleased to continue our three-part series about how patients and researchers can work together to develop clinical trials. In this second video, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to show how researchers and patient advocates can be empowered with tools to create clinical trials that resonate with patients and address the key issues they care about. If you missed the first video, How Can Patients and Researchers Design Clinical Trials Together, you can watch it here. Watch Part 2 below, or use the timestamps to skip to a

Read time: 3 minutes. Throughout 2024 we published blogs sharing scientific meeting recaps, educational content, personal stories, treatment news, and so much more. Below are the most popular articles we published in 2024. If you’re looking for survivor features and personal stories, you can see all the lung cancer survivors we highlighted in 2024 right here. 2024 ASCO: Highlights of Lung Cancer Research In June, we recapped the annual American Society of Clinical Oncology meeting. Thousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates

LUNGevity had a tremendous year supporting impactful research in 2024. In addition to our existing portfolio of ongoing research grants, we issued several new research awards in 2024. All of these awards are in strategic areas of research that are likely to move the dial for people living with lung cancer today and those who will be diagnosed in the future. Below are more details about the research projects we recently announced funding for. LUNGevity Supports 10 New Research Projects Totaling $3,141,656 In 2024 Early Detection LUNGevity and our partner, Rising Tide for Clinical Cancer